Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

Saved in:

Bibliographic Details
Published in:	Cancer cell Vol. 40; no. 6; p. 590
Main Authors:	Stuver, Robert, Shah, Gunjan L, Korde, Neha S, Roeker, Lindsey E, Mato, Anthony R, Batlevi, Connie L, Chung, David J, Doddi, Sital, Falchi, Lorenzo, Gyurkocza, Boglarka, Hamilton, Audrey, Lin, Ya-Hui, Jakubowski, Ann A, Joffe, Erel, Landau, Heather L, Lin, Richard J, Mailankody, Sham, Palomba, M Lia, Park, Jae H, Perales, Miguel-Angel, Ponce, Doris M, Ramanathan, Lakshmi V, Salles, Gilles A, Scordo, Michael, Seo, Susan K, Shah, Urvi A, Stein, Eytan M, Straus, David, Usmani, Saad Z, Young, James W, Zelenetz, Andrew D, Noy, Ariela, Vardhana, Santosha A
Format:	Journal Article
Language:	English
Published:	United States 13.06.2022
Subjects:	Antibodies, Monoclonal Antibodies, Neutralizing COVID-19 Drug Treatment Drug Combinations Hematologic Neoplasms - drug therapy Humans SARS-CoV-2
ISSN:	1878-3686, 1878-3686
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Correspondence-1 content type line 23
ISSN:	1878-3686 1878-3686
DOI:	10.1016/j.ccell.2022.05.007